Premium
Cytokines and cross‐linking of sIgM augment PMA‐induced activation of human leukaemic CD5 + B cells
Author(s) -
Tangye Stuart G,
Weston Kathryn M,
Raison Robert L
Publication year - 1997
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1038/icb.1997.87
Subject(s) - cd5 , microbiology and biotechnology , in vitro , b cell , cytokine , biology , antibody , chemistry , immunology , biochemistry
Purified leukaemic CD5+ B cells obtained from patients with B cell chronic lymphocytic leukaemia (B‐CLL) undergo activation and differentiation following in vitro stimulation with optimal concentrations of the phorbol ester PMA. This paper examines the ability of exogenous cytokines, anti‐Ig antibodies, or combinations of these, to enhance or replace the activation signal provided by PMA to different populations of leukaemic B cells. Proliferation induced by PMA was enhanced 2–20‐fold when the cells were co‐cultured with either anti‐Ig, IL‐2, IL‐4. IL‐I3. IFN‐γ or TNF‐α. Moreover, the combination of anti‐Ig. PMA and any one of the above cytokines further enhanced proliferation. Anti‐Ig and exogenous cytokines were also capable of inducing proliferation in leukaemic B cells cultured with a non‐mitogenic concentration of PMA. When taken together with the finding that IL‐2, IL‐4, IL‐13, IFN‐γ and TNF‐a prevent in vitro apoptosis of leukaemic CD5+ B cells, the results presented here suggest that these cytokines, in conjunction with signals delivered via sig, may play a role in the proliferation of leukaemic B cells in vivo and. consequently, the pathogenesis of B‐CLL.